Therapeutic vaccines for prostate cancer
Related Experiment Video
Updated: Aug 8, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Christopher P Tarassoff1, Philip M Arlen, James L Gulley
1F.A.C.P., National Cancer Institute, Clinical Immunotherapy Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, 10 Center Drive, MSC 1750, Building 10, Room 5B52, Bethesda, Maryland 20892, USA.
Abstract:
Prostate cancer is the most common, noncutaneous cancer for men in the U.S., leading to more than 30,000 deaths a year. Vaccines for prostate cancer, which for several years have been shown to generate immunologic responses, are beginning to show significant clinical promise. At present, numerous therapeutic options are being investigated, including autologous and allogeneic whole-tumor cell vaccines, dendritic cell vaccines, and poxvirus-based vaccines. Advances in basic immunology have translated into new, more complex therapeutic strategies. The findings from current trials and the demonstrated potential to combine vaccines with conventional therapies herald a promising future for the treatment of prostate cancer. This review highlights recent advances and clinical trials in immunotherapy for prostate cancer, along with current thoughts on immunologic and clinical monitoring of these trials.
Insights
Prostate cancer immunotherapy, including various vaccines, shows significant clinical promise. Advances in immunology are leading to new strategies and combination therapies for effective treatment.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Prostate cancer is a leading cause of cancer death in U.S. men.
- Immunotherapy, specifically vaccines, has demonstrated immunologic responses.
- Existing research explores diverse vaccine types like whole-tumor cell and dendritic cell vaccines.
Purpose of the Study:
- To review recent advances in prostate cancer immunotherapy.
- To highlight ongoing clinical trials in this field.
- To discuss immunologic and clinical monitoring strategies for trials.
Main Methods:
- Review of current scientific literature and clinical trial data.
- Analysis of different immunotherapy approaches for prostate cancer.
- Examination of immunological and clinical endpoints.
Main Results:
- Prostate cancer vaccines are showing increasing clinical promise.
- New, complex therapeutic strategies are emerging from immunological advances.
- Combination therapies with conventional treatments are being investigated.
Conclusions:
- Immunotherapy, particularly vaccines, offers a promising future for prostate cancer treatment.
- Continued research and clinical trials are essential for advancing treatment options.
- Effective monitoring is crucial for evaluating the success of immunotherapies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...